Suicidal thoughts require prompt clinical attention, but they do not look the same for every person. They can range from a passive wish not to wake up to active thoughts involving a plan, access to lethal means, or an intention to act. Those differences affect what level of care is appropriate.
If you or someone else may act on suicidal thoughts, has a plan or access to means, or cannot remain safe, call 911 or go to the nearest emergency department. You can also call or text 988 to reach the Suicide & Crisis Lifeline. Do not wait for a scheduled appointment or ketamine consultation.
At Taconic Psychiatry in Manchester, Vermont, we provide outpatient psychiatric care for selected patients experiencing suicidal ideation. Intramuscular ketamine may be considered when clinically appropriate, but it is not emergency crisis stabilization, a substitute for hospitalization, or a stand-alone solution.
Research suggests that ketamine can reduce suicidal thoughts quickly in some adults. The same research also leaves important questions unanswered about durability, treatment route, long-term safety, and whether a reduction in thoughts leads to fewer suicide attempts or deaths.
What Clinical Research Supports
The strongest evidence for ketamine and suicidal ideation comes from controlled studies using intravenous administration.
A randomized trial involving 80 adults with major depressive disorder and clinically significant suicidal thoughts compared one IV ketamine infusion with an active control medication. At 24 hours, the ketamine group experienced a greater reduction in suicidal ideation, and more participants met the study’s response threshold.
A larger hospital-based trial enrolled 156 adults experiencing severe suicidal ideation across several diagnostic groups. Participants received two IV ketamine or placebo infusions in addition to their usual care. More people receiving ketamine reached the study’s definition of remission from suicidal ideation by the third day.
These findings are clinically meaningful because some standard antidepressant treatments may require several weeks before their full effect can be evaluated. In certain studies, changes after ketamine were detected within hours or by the following day.
However, the research does not show that every patient will respond. It also does not establish that ketamine is the right first intervention for someone in immediate danger.
Our discussion of the science behind ketamine therapy provides additional background on glutamate signaling and why ketamine has attracted attention as a rapid-acting psychiatric treatment.
Reduced Suicidal Thoughts Do Not Equal Proven Suicide Prevention
Suicidal ideation is an important clinical outcome, but it is not the same as suicidal behavior.
A person may report fewer thoughts after treatment while still facing significant risk related to impulsivity, substance use, access to lethal means, recent loss, agitation, psychosis, mixed mood symptoms, or an unstable home environment. Conversely, some people attempt suicide without reporting persistent or easily detected ideation beforehand.
The large hospital trial found a clear short-term difference in suicidal ideation, but suicide-attempt rates during follow-up were similar between treatment groups. A 2025 systematic review likewise found that recent ketamine trials measured suicidal thoughts rather than suicide attempts or deaths as treatment outcomes.
This means the evidence supports a more limited conclusion: ketamine may reduce suicidal ideation for some patients over a short period. Research has not established that ketamine prevents suicide.
We therefore do not use a lower symptom score as the only measure of safety. Continued risk assessment, support, follow-up, and treatment of the underlying psychiatric condition remain necessary even when thoughts improve quickly.
Is the Effect Separate From Improvement in Depression?
Suicidal thoughts commonly occur alongside depression, but they may also appear with bipolar disorder, trauma-related conditions, substance use, psychosis, severe anxiety, personality pathology, medical illness, or acute life stress.
Some analyses suggest that ketamine’s effect on suicidal thoughts may be partially independent of its broader antidepressant effect. In one randomized trial, improvement in depression explained only part of the reduction in suicidal ideation.
That finding is interesting, but it does not establish a separate, fully understood antisuicidal mechanism. Ketamine affects glutamate-related signaling and several downstream biological processes, while suicidal thinking is shaped by complex psychological, social, and clinical factors.
We avoid claims that ketamine targets a specific “suicide circuit,” removes despair directly, or neurologically resets a patient. Those explanations go beyond what current research can demonstrate.
For patients whose suicidal thoughts occur within a depressive illness, our approach also includes a broader evaluation of depression symptoms and treatment history. Patients dealing with treatment-resistant depression may also benefit from reviewing our overview of treatment-resistant depression integrative care.
Why the Route of Administration Matters
Most of the strongest controlled evidence for suicidal ideation involves IV ketamine. At Taconic Psychiatry, our in-office service includes intramuscular ketamine injections.
Both routes deliver ketamine systemically, but they are not interchangeable.
An IV infusion enters the bloodstream continuously over a set period and can be adjusted or stopped while it is being administered. An IM dose is injected into muscle and absorbed afterward, so it cannot be modified in the same way once given.
The routes may also differ in onset, peak effects, bioavailability, treatment experience, and the amount of condition-specific research available. Results from an IV study cannot automatically be used to promise the same outcome from an IM protocol.
Recent research reviews include trials using several routes, but direct evidence for IM ketamine and suicidal ideation remains much more limited. That gap is part of the informed-consent conversation.
Ketamine is approved as an anesthetic. Its use for suicidal ideation and other psychiatric indications is off-label. Off-label prescribing can be clinically appropriate, but it requires careful evaluation, a clear rationale, and an honest discussion of what is and is not known.
Outpatient Ketamine Is Not Emergency Crisis Care
The phrase “rapid-acting” can create a dangerous misunderstanding. A treatment that has produced changes within hours in clinical trials is not necessarily an appropriate intervention for someone who may attempt suicide now.
Our outpatient clinic cannot replace:
- Emergency medical evaluation
- Continuous observation
- Inpatient psychiatric care
- Removal of immediate access to lethal means
- Medically supervised withdrawal treatment
- Other urgent interventions appropriate to the situation
When a patient reports suicidal thoughts, the first question is not simply whether ketamine might help. The first question is whether that person can be treated safely in an outpatient setting.
Someone with active intent, a specific plan, immediate access to means, severe intoxication, uncontrolled psychosis, extreme agitation, or an inability to participate in a safety plan may need a higher level of care.
Ketamine may be considered later as part of ongoing treatment, but it should not delay emergency intervention.
How We Assess Whether Outpatient Treatment Fits
We approach suicidal ideation through a comprehensive psychiatric evaluation rather than a single symptom checklist.
Our assessment may include:
- The nature, frequency, and intensity of suicidal thoughts
- Whether the thoughts are passive or active
- The presence of intent, planning, preparation, or access to means
- Previous suicide attempts or self-harm
- Recent hospitalizations or emergency evaluations
- Current depression, bipolar, trauma-related, psychotic, or anxiety symptoms
- Agitation, impulsivity, hopelessness, and changes in sleep
- Alcohol, drug, and prescribed-medication use
- Medical conditions and current medications
- Available family, social, and professional support
- The patient’s ability to attend follow-up appointments
- Whether another provider is already managing part of the care plan
- Whether outpatient treatment remains safe as circumstances change
A diagnosis or history of treatment resistance does not automatically establish candidacy. Two patients describing similar thoughts may require very different recommendations based on intent, history, supports, medical risk, and current stability.
We may recommend emergency evaluation, hospitalization, another psychiatric intervention, coordination with an existing treatment team, or additional stabilization before ketamine is considered. We may also determine that ketamine is not appropriate.
What Monitoring Can and Cannot Provide
During in-office IM treatment, patients are observed by our clinical team in a controlled setting. Monitoring can help us identify temporary cardiovascular, perceptual, emotional, or dissociative effects and respond to concerns arising during the session.
That observation is important, but it does not remove all risk after a patient leaves the office.
Suicidal thoughts can fluctuate. A patient may improve briefly and then experience a return of symptoms. Stress, substance use, medication changes, conflict, sleep loss, or another mood shift may also change the risk picture between appointments.
For this reason, the plan may involve:
- Ongoing psychiatric follow-up
- Repeated assessment of suicidal thoughts and intent
- Coordination with a therapist or other prescriber
- A personalized crisis or safety plan
- Support-person involvement when appropriate and authorized
- Review of access to lethal means
- Clear instructions about when to seek emergency care
- Continued treatment of the underlying psychiatric condition
Patients considering ketamine for the first time may find our guide to preparing for ketamine therapy helpful, but general preparation information does not replace an individual risk assessment.
Ketamine Belongs Within a Broader Treatment Plan
Suicidal ideation is not a diagnosis by itself. Effective treatment requires understanding what is contributing to the thoughts and what keeps the person safe.
A broader plan may include psychiatric medication, psychotherapy, treatment of a substance use disorder, sleep stabilization, family involvement, medical care, social support, or a higher level of psychiatric treatment.
Ketamine may create a period of symptom improvement for some patients, but it cannot resolve every contributor to suicidal distress. It does not repair a dangerous living situation, replace meaningful relationships, reverse financial or legal stress, or eliminate the need to address trauma and other psychiatric symptoms.
Our integrative psychiatry model helps us consider biological, psychological, relational, social, medical, and lifestyle factors together. Ketamine, when used, remains one element of that plan.
We do not promise that psychotherapy or integrative care will make ketamine’s effect permanent. We do believe that ongoing care is necessary because the research describes ketamine’s effect on suicidal ideation as variable and often time-limited.
Stigma Should Not Prevent Honest Disclosure
Some people avoid discussing suicidal thoughts because they fear judgment, loss of privacy, or automatic hospitalization.
Not every disclosure leads to the same clinical response. Passive thoughts without intent may be managed differently from an immediate plan to act. At the same time, we cannot promise that hospitalization will never be recommended. When we believe someone cannot remain safe in outpatient care, we have a responsibility to recommend a more protective setting.
Honest information helps us distinguish between these situations. We want patients to tell us when thoughts have changed, when a plan has developed, when access to means has increased, or when substance use and impulsivity are making safety harder to maintain.
Our goal is to meet that disclosure with compassion and directness. Asking about suicide does not make the thoughts more real. It gives us information needed to respond appropriately.
Cost and Access for Vermont Patients
Travel can complicate psychiatric care in Vermont, particularly when treatment requires repeated in-person visits and someone lives far from Manchester.
Cost can also be a barrier. Taconic Psychiatry does not accept insurance, including Medicare or Medicaid. Patients are responsible for payment, and possible out-of-network reimbursement depends on the individual insurance plan and is not guaranteed.
We discuss fees and the expected treatment structure before a patient begins. Cost should never lead someone in immediate danger to postpone emergency care while considering an outpatient ketamine service.
When urgent help is needed, call 911, go to the nearest emergency department, or call or text 988.
Common Questions About Ketamine and Suicidal Ideation
Does ketamine reduce suicidal thoughts, or only depression?
Controlled studies have found reductions in suicidal ideation after IV ketamine. Some analyses suggest that improvement in depression explains only part of that change. The relationship remains under study, and we cannot promise a distinct antisuicidal effect for an individual patient.
Is IM ketamine appropriate for someone who is actively suicidal?
There is no universal answer based solely on the phrase “actively suicidal.” A patient with immediate intent, a plan, access to means, or an inability to remain safe needs emergency evaluation rather than a routine outpatient ketamine appointment. Selected patients with persistent or recurrent suicidal thoughts may be evaluated for outpatient IM treatment when their current risk, supports, medical condition, and broader care plan make that setting appropriate.
Is the evidence for IM ketamine the same as the evidence for IV ketamine?
No. Most of the strongest controlled research on suicidal ideation has used IV ketamine. IM ketamine has a related pharmacological rationale, but route-specific evidence is more limited. We explain that limitation rather than assuming identical outcomes.
How quickly can suicidal thoughts improve?
Some IV studies detected meaningful group-level changes within hours or by the next day. That does not guarantee rapid improvement for every patient. Some people do not respond, and others experience benefits that diminish over time.
How long can the effect last?
Duration varies. Studies have reported effects lasting from hours or days to several weeks in some participants, particularly with repeated treatment and ongoing care. Research has not established a universal duration or maintenance schedule for IM ketamine used for suicidal ideation.
Does ketamine prevent suicide attempts?
Research has not established that ketamine prevents suicide attempts or suicide deaths. A decrease in reported thoughts is clinically valuable, but safety planning, follow-up, treatment of the underlying condition, and emergency intervention when needed remain essential.
How many IM sessions will I need?
There is no evidence-based IM session count that applies to every patient experiencing suicidal ideation. We base recommendations on the evaluation, treatment goals, response, tolerability, changing risk, and the role ketamine is intended to play within the larger care plan.
Will insurance cover treatment?
Taconic Psychiatry does not accept insurance. Patients pay directly and may seek possible out-of-network reimbursement when their plan allows. Coverage and reimbursement are not guaranteed, particularly for off-label ketamine treatment.
What Vermont Patients Should Remember
- Suicidal thoughts require prompt attention, and immediate danger requires emergency care.
- Call 911 or go to an emergency department when someone may act on suicidal thoughts or cannot remain safe.
- Call or text 988 for free, confidential crisis support in the United States.
- Controlled studies suggest IV ketamine can reduce suicidal ideation quickly in some adults.
- Reduced ideation has not been proven to prevent suicide attempts or deaths.
- The strongest research involves IV treatment; direct evidence for IM ketamine is more limited.
- Ketamine’s psychiatric use is off-label.
- Outpatient IM ketamine is not crisis stabilization or a replacement for hospitalization.
- Careful assessment, monitoring, follow-up, and treatment of the underlying condition remain necessary.
- Results vary, and ketamine is not appropriate for everyone.
A Careful, Evidence-Informed Conversation
The research on ketamine and suicidal ideation deserves attention. Controlled studies have found rapid reductions in suicidal thoughts, addressing a symptom for which clinicians have long needed faster treatment options.
The same evidence requires humility. Benefits may be temporary. Most trials used IV administration. Study participants received ketamine within structured clinical care, and improvement in thoughts did not prove that future suicidal behavior was prevented.
At Taconic Psychiatry, we approach IM ketamine as one possible component of comprehensive outpatient care—not as a rescue service, guarantee, or substitute for emergency treatment.
For persistent or recurrent suicidal thoughts that are not an immediate emergency, Vermont patients may schedule a consultation to ask whether an outpatient psychiatric evaluation is appropriate.
When safety cannot wait, call 911, go to the nearest emergency department, or call or text 988.
About Adam Pruett, MD, MPH
Adam Pruett, MD, MPH, graduated magna cum laude from Birmingham-Southern College with a BA in German. He completed medical school at the University of Alabama and his psychiatry residency at Emory University, where he served as chief resident at Grady Hospital and helped teach and supervise physicians in training.
Dr. Pruett spent more than 10 years working primarily in inpatient psychiatric settings in Alabama and Vermont. He later completed an immersive, year-long fellowship with the Integrative Psychiatry Institute.
Dr. Pruett co-founded Taconic Psychiatry in Manchester, Vermont, with his colleague Ben Stillman, PsyD. Our practice offers integrative psychiatry, psychotherapy, at-home ketamine protocols, and in-office intramuscular ketamine treatment.
Works Cited
Abbar, M., Demattei, C., El-Hage, W., et al. (2022). Ketamine for the acute treatment of severe suicidal ideation: Double-blind, randomised placebo-controlled trial. BMJ, 376, e067194.
Grunebaum, M. F., Galfalvy, H. C., Choo, T. H., et al. (2018). Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial. The American Journal of Psychiatry, 175(4), 327–335.
National Institute of Mental Health. (2025). Warning signs of suicide.
Sajid, S., Mann, J. J., & Grunebaum, M. F. (2025). Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: A systematic review. Translational Psychiatry, 15, 44.
Sanacora, G., Frye, M. A., McDonald, W., et al. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399–405.
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. The American Journal of Psychiatry, 175(2), 150–158.
Medical Disclaimer
The information provided in this blog is for educational purposes only and does not constitute medical advice, diagnosis, emergency evaluation, or treatment. Ketamine for suicidal ideation is an off-label psychiatric use and is not appropriate for everyone. Treatment outcomes vary.
If you or someone else may act on suicidal thoughts, has a plan or access to means, or cannot remain safe, call 911 or go to the nearest emergency department. In the United States, call or text 988 to reach the Suicide & Crisis Lifeline. Do not delay emergency care while waiting for a scheduled appointment or consultation.